V. Ferenc

Polo-like kinase-1 as a novel target in neoplastic mast cells: demonstration of growth-inhibitory effects of small interfering RNA and the Polo-like kinase-1 targeting drug BI 2536

W. Pickl, P. Valent, K. Gleixner, 2011, Haematologica.

Targeting of heat-shock protein 32/heme oxygenase-1 in canine mastocytoma cells is associated with reduced growth and induction of apoptosis.

H. Maeda, W. Pickl, P. Valent, 2008, Experimental hematology.

Polo-like kinase 1 (Plk1) as a novel drug target in chronic myeloid leukemia: overriding imatinib resistance with the Plk1 inhibitor BI 2536.

Christian Sillaber, Peter Valent, W. Pickl, 2010, Cancer research.

Dasatinib inhibits the growth and survival of neoplastic human eosinophils (EOL-1) through targeting of FIP1L1-PDGFRalpha.

G. Superti-Furga, K. Bennett, W. Pickl, 2008, Experimental hematology.

Identification of proapoptotic Bim as a tumor suppressor in neoplastic mast cells: role of KIT D816V and effects of various targeted drugs.

W. Pickl, P. Valent, C. Sillaber, 2009, Blood.

Polo-like kinase 1 (Plk1) as a novel drug target in chronic myeloid leukemia: overriding imatinib resistance with the Plk1 inhibitor BI 2536.

W. Pickl, P. Valent, C. Sillaber, 2010, Cancer research.

Lenalidomide therapy in systemic mastocytosis.

H. Kluin-Nelemans, P. Valent, C. Akin, 2009, Leukemia research.